Mitsubishi UFJ Trust & Banking’s Spyre Therapeutics SYRE Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Buy	+1,844	New	+$135K	﹤0.01%	1380

Other funds holding SYRE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's SYRE Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 1,844 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #1380 among its holdings.

64 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 1,844 shares of Spyre Therapeutics worth $164K as of Q2 2026.
Spyre Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1380 holding.
64 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.